

May 19, 2025

To whom it may concern:

Company name: ROHTO Pharmaceutical Co., Ltd.
 Representative: Masashi Sugimoto, President and COO
 (Code: 4527 TSE Prime)
 Contact: Masaya Saito, Vice President and CFO
 (TEL: +81-6-6758-8223)

Notice of Dividend of Surplus

ROHTO PHARMACEUTICAL CO., LTD. are pleased to announce the resolution made at the Board of Directors meeting held today to pay dividends from retained earnings with a record date of March 31, 2025, as follows.

Details of dividends

	Determined amount	Most recent dividend forecast (Announced on May 13, 2025)	Results for the previous fiscal year (Year ended March 31, 2024)
Record date	March 31, 2025	Same as left	March 31, 2024
Year-end dividend per share	20yen	20yen	15yen
Total dividends	4,519 million yen	4,519 million yen	3,422 million yen
Effective date	Jun 12, 2025	—	Jun 13, 2024
Sources	Retained earnings	—	Retained earnings

(Reference) Breakdown of Annual Dividends

	Dividend per share		
Record date	2nd quarter-end	Year-end	Total
Results for the previous fiscal year (Year ended March 31, 2024)	12yen	15yen	27yen
Results for the fiscal year under review	16yen	20yen	36yen
Forecast for the coming year (Year ended March 31, 2026)	21yen	21yen	42yen